All In Biotech

Drug Trial Radar · NCT03228940

Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease

An Open-Label Study to Assess the Safety and Effect on Key Biomarkers of Oral RVX000222 in Subjects With Fabry Disease

Last checked: Nov 19, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Nov 22, 2022

Primary completion

Nov 22, 2022

Study completion Nov 22, 2022

Sponsor

Lead sponsor
Resverlogix CorpIndustry
Sponsor type
Industry
First posted
Jul 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Fabry Disease (FD) is a rare X-linked lysosomal storage disorder (LSD) caused by mutations in the GLA gene which translates into decreased activity or lack of function of the enzyme alpha-galactosidase A (α-GAL A) and accumulation of the enzymes substrate, i.e., Gb3, throughout the body. Cardiovascular and renal complications are among the leading causes of death in FD patients. RVX000222 is a BET inhibitor which modulates the expression of a variety of genes and, due to its effects on pathways downstream of substrate accumulation and reduction of major cardiac events, holds promise as a potential add-on therapy to accompany enzyme replacement therapy (ERT) in FD patients.

Conditions

  • Fabry Disease

Interventions

  • RVX000222Drug

    oral, BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: 16 weeks
  2. Changes in clinical laboratory parametersTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Queen Elizabeth II Health Sciences Centre, Victoria General Site

    Halifax, Nova Scotia, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.